(Q36720269)

15 August 2017

title

Anticonvulsants in sports: ethical considerations (English)

1 reference

15 August 2017

0 references

Kenneth R Kaufman

1

1 reference

15 August 2017

publication date

26 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

10

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

268-271

1 reference

Modafinil in sports: ethical considerations

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Selective blockade of N-type calcium channels by levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Effect of the New Antiepileptic Drug Levetiracetam in an Animal Model of Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Levetiracetam for treatment-refractory posttraumatic stress disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Monotherapy treatment of bipolar disorder with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Levetiracetam in the treatment of rapid cycling bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

An open-label study of tiagabine as augmentation therapy for anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Tiagabine in treatment refractory bipolar disorder: a clinical case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine: a review of its use in bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine augmentation in unipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine augmentation strategy for patients with treatment-resistant depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The potential role of lamotrigine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The epidemiology of the comorbidity of epilepsy in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Anxiety in patients with epilepsy: systematic review and suggestions for clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Diagnosis and treatment of mood disorders in persons with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The presence and clinical implications of depression in a community population of adults with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Antiepileptic drugs in psychiatry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Phenytoin as an antimanic anticonvulsant: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

The use of primidone in the treatment of refractory bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Placebo-controlled study of gabapentin treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

An open prospective study of zonisamide in acute bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Doping control from a global and national perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Open-label tiagabine monotherapy for major depressive disorder with anxiety

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Lamotrigine as an augmentation agent in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.12.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEBEH.2006.12.004

1 reference

15 August 2017

1 reference